Literature DB >> 17031300

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.

Ketan Laud1, Richard F Spaide, K Bailey Freund, Jason Slakter, James M Klancnik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17031300     DOI： 10.1097/01.iae.0000240121.28034.c3

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  18 in total

1.  Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Gulnar Hafiz; Diana V Do; Julia A Haller; Roberto Pili; Ingrid E Zimmer-Galler; Kashif Janjua; R C Andrew Symons; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2007-12-11       Impact factor: 5.258

2.  Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors:  Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

3.  Treatment of myopic choroidal neovascularization with posterior sub-Tenon's bevacizumab injection (Avastin ®).

Authors:  I-Chia Liang; Yu-Ying Chang; Tong-Sheng Lee; Yi-Ru Lin; Kwan-Rong Liu
Journal:  Int Ophthalmol       Date:  2014-02-02       Impact factor: 2.031

4.  Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome.

Authors:  Jose M Ruiz-Moreno; Javier A Montero
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-10       Impact factor: 3.117

5.  Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Noriaki Shimada; Muka Moriyama; Wakako Hara; Takeshi Yoshida; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-16       Impact factor: 3.117

6.  Intravitreal bevacizumab: an analysis of the evidence.

Authors:  Derrick P Smit; David Meyer
Journal:  Clin Ophthalmol       Date:  2007-09

7.  Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

8.  [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia].

Authors:  S Dithmar; K B Schaal; A E Höh; S Schmidt; F Schütt
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

9.  Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis.

Authors:  Salim Ben Yahia; Carl P Herbort; Salah Jenzeri; Kamel Hmidi; Sonia Attia; Riadh Messaoud; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2008-04-10       Impact factor: 2.031

10.  Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection.

Authors:  Eun Jee Chung; Hyoung Jun Koh
Journal:  Korean J Ophthalmol       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.